Dataset Information

Identification of STN1 interactiome in response to DNA damage in pancreatic cancer cells

ABSTRACT: STN1 is known to play a critical role in DNA damage response, however, the mechanisms by which this is performed, specifically in the context of pancreatic cancer are not well understood. Here we studied the changes in STN1 interactome in control and in the response to DNA-damage causing stimuli.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Ductal Cell, Cell Culture

DISEASE(S): Pancreatic Ductal Adenocarcinoma

SUBMITTER: Krystine Mansfield

LAB HEAD: Patrick Pirrotte

PROVIDER: PXD060475 | Pride | 2025-10-13

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	141_0001_01A_R_SampleARep1FrA_06AUG21_CELL_HUM_ECL_0002_01AN_60MIN_MNM_RS_01.raw	Raw
	141_0001_01A_R_SampleARep1FrB_06AUG21_CELL_HUM_ECL_0002_01AN_60MIN_MNM_RS_01.raw	Raw
	141_0001_01A_R_SampleARep1FrC_06AUG21_CELL_HUM_ECL_0002_01AN_60MIN_MNM_RS_01.raw	Raw
	141_0001_01A_R_SampleARep1FrD_06AUG21_CELL_HUM_ECL_0002_01AN_60MIN_MNM_RS_01.raw	Raw
	141_0001_01A_R_SampleARep1FrE_06AUG21_CELL_HUM_ECL_0002_01AN_60MIN_MNM_RS_01.raw	Raw

Items per page:

1 - 5 of 70

Publications

KRAS-induced STN1 (OBFC1) promotes proper CTC1-STN1-TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic cancer.

Shen Changxian C Cui Tiantian T Yang Linlin L Gui Ling L Corrales-Guerrero Sergio S Nair Sindhu S Li Haiqing H Karasinska Joanna M JM Topham James T JT Renouf Daniel J DJ Schaeffer David F DF Fernandez Anthony A Ping Xiaoli X Shen Binghui B Stark Jeremy M JM Williams Terence M TM

Nucleic acids research 20250901 18

KRAS activating mutations occur in 90%-95% of pancreatic adenocarcinoma (PC) and contribute to tumor progression and resistance to therapy, including radiotherapy. A screen in isogenic cells revealed that KRAS activation positively modulates STN1 expression, a component of the CTC1-STN1-TEN1 (CST) complex. We find that STN1 is significantly upregulated in PC and its elevation is correlated with KRAS oncogenic mutations, while inhibition of KRAS signaling decreases STN1 expression. Interestingly, ...[more]

PMID: 41036624

Similar Datasets

Project description:The cell division cycle is tightly controlled in normal cells. Cancer cells are characterized by deregulation in cell division cycle, which is associated with increased DNA replication and elevated cellular proliferation. Recently, genetic studies indicate that cyclin dependent kinases CDK2, CDK4 and CDK6 are not essential for the mammalian cell cycle, instead, they are only required for the proliferation of specific cell types.Thus, targeting the activities of CDK2, CDK4 and CDK6 may be a promising approach for cancer treatment. Rocaglamides (Roc) (= Flavaglines), derived from the traditional Chinese medicinal plant Aglaia, are a group of naturally occurring herbal chemicals characterized by a cyclopenta[b]benzofurans skeleton. A number of Roc derivatives have been found to have potent inhibitory effects on tumor growth with IC50 concentrations at the nM rages. Roc-mediated inhibition of proliferation was first found to be associated with inhibition of protein synthesis in 1998. In this study, using the representative Roc-A compound we revealed a novel mechanistic function of Roc. We show that Roc-A induces rapid activation of ATM (ataxiatelangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-related) kinases. Activated ATM and ATR in turn activate the downstream checkpoint kinases CHK1 and CHK2. The latter then phosphorylate Cdc25A that leads to a phosphorylation-mediated degradation of Cdc25A. Usually, ATR and ATM are activated in response to DNA damage. However, in this study we show that Roc-A does not directly induce DNA breaks. To elucidate the molecular mechanism by which Roc-A activates ATM and ATR we performed a time-resolved microarray analysis to compare Roc-A-inducible genes in malignant vs. normal T lymphocytes. Based on the dynamic gene responses we found that Roc-A stimulates in Jurkat, but not in normal T lymphocytes, a set of genes responsive to DNA damage and nucleotide excision repair. This finding provides a hint of the molecular bases for Roc-induced activation of ATM and ATR. This finding also revealed a new scope for cancer treatment using Roc-A. The isolation time points for Roc A treated D6 T-cells were recorded at t=[1,2,3,4,6,8,10,14,20,28,36] hours after stimulation. Post-stimulation time points for Jurkat cells are t=[0.5,1,2,3,4,5,6,7,8,10,12,14,16,20,24,28,32,36]. Unstimulated control time points were taken at t=[0,4,10,16,24,36] hours for Jurkat cells at t=[0,6,14,24,36] hours.

Project description:Esophageal cancers (ECs) are highly aggressive tumors with poor prognosis and few treatment options. This study investigated the possibility of treating esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) cells by inhibitors of broad and specific histone deacetylases (HDACi; SAHA, MS-275, FK228) and/or of DNMT (Azacytidine, AZA). Drug targets (HDAC1,2,3 and DNMT1) were present in non-neoplastic (HET-1A), ESCC (OE21) and EAC (OE33) cell lines. All cell lines responded to HDACi by reduced HDAC activity and increased histone acetylation as well as to AZA by up-regulation of p21. Expression of drug targets remained largely unaffected by HDACi and AZA treatment. Importantly, cell viability, apoptosis, cell cycle dynamics and DNA damage were only affected by HDACi and/or AZA in ESCC and EAC, but not the non-neoplastic cells. This was specifically seen for the combination of MS-275 and AZA, leading to enhanced cancer cell selectivity and drug efficiency. By transcriptome analyses of MS-275, AZA and MS-275/AZA treated cells, known (e.g. p21) as well as novel regulated genes significantly associated with the cellular effects post HDACi and/or AZA treatment in ESCC and EAC cells were identified. Finally, human EC tissue specimens frequently expressed the actionable drug targets HDAC1/2/3 and DNMT1. In summary, a combined HDACi (MS-275)/AZA treatment is cancer cell selective and efficient in vitro. Since the majority of ECs express the drug targets in situ, this paves the way for further investigations of HDACi/AZA treatment in esophageal cancer cells and their translation into a clinico-pathological setting. To elucidate the transcriptome response to HDAC inhibitors of normal esophageal cells and esophageal tumor cells, total RNA was isolated from non-neoplastic esophageal epithelial cells (Het1A cells) a well as from two esophageal tumor cell lines (OE21 and OE33), respectively. Cells were treated with either MS-275, Azacytidine (AZA) or in combination of both. DMSO treatment was used as control in each case. Total RNA was isolated from cells 24 h after treatment and experiments were performed in biological triplicates.